Non-infectious Uveitis
Conditions
Brief summary
This observational study will evaluate the safety, efficacy, characteristics of patients, characteristics of physicians and quality of life in patients who are prescribed OZURDEX® as treatment for non-infectious uveitis of the posterior segment of the eye in France.
Interventions
DRUGdexamethasone intravitreal implant
Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
Sponsors
Allergan
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
-Patient with non-infectious uveitis affecting the posterior segment of the eye.
Exclusion criteria
-Patient not residing in metropolitan France.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants with Best Corrected Visual Acuity (BCVA) ≥15 Letters | 2 Months |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in BCVA | Baseline, Months 2, 6 and 18 |
| Change from Baseline in Vitreous Haze Score Using a 5-Point Scale | Baseline and Months 2, 6 and 18 |
| Change from Baseline in Macular Thickness | Baseline, Months 2, 6 and 18 |
| Percentage of Participants Categorized by Comorbidities (Diseases Associated with Inflammation, Other Ophthalmic Diseases, General Comorbidities) | 18 Months |
| Percentage of Participants with a Gain (Improvement) in BCVA of at Least 15 Letters from Baseline | Baseline, Months 6 and 18 |
| Number of Repeat Treatments with OZURDEX® and Other Drugs | 18 Months |
| Time Between Repeat Treatments with OZURDEX® and Other Drugs | 18 Months |
| Percentage of Participants with Adverse Events (AEs) | 18 Months |
| Change from Baseline in the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ25) Score Using a 25 Item Questionnaire | Baseline, Months 2 and 18 |
Countries
France
Outcome results
None listed